[1] BASSETTI C L A, ADAMANTIDIS A, BURDAKOV D, et al. Narcolepsy: clinical spectrum, aetiopathophysiology, diagnosis and treatment[J]. Nat Rev Neurol, 2019, 15: 519-539.
[2] VIDENOVIC A, NOBLE C, REID K J, et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease[J]. JAMA Neurol, 2014, 71(4): 463-469. doi:  10.1001/jamaneurol.2013.6239
[3] BUBU O M, ANDRADE A G, UMASABOR-BUBU O Q, et al. Obstructive sleep apnea, cognition and Alzheimer’s disease: a systematic review integrating three decades of multidisciplinary research[J]. Sleep Med Rev, 2020, 50: 101250. doi:  10.1016/j.smrv.2019.101250
[4] KRAUSE A J, SIMON E B, MANDER B A, et al. The sleep-deprived human brain[J]. Nat Rev Neurosci, 2017, 18(7): 404-418. doi:  10.1038/nrn.2017.55
[5] HAVEKES R, PARK A J, TUDOR J C, et al. Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1[J]. eLife, 2016, 5: e13424. doi:  10.7554/eLife.13424
[6] BATTLEDAY R M, BREM A K. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review[J]. Eur Neuropsychopharmacol, 2016, 26(2): 391. doi:  10.1016/j.euroneuro.2015.12.023
[7] PASSANI M B, LIN J S, HANCOCK A, et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders[J]. Trends Pharmacol Sci, 2004, 25(12): 618-625. doi:  10.1016/j.tips.2004.10.003
[8] PARMENTIER R, ZHAO Y, PERIER M, et al. Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: a study using a knockout mouse model[J]. Neuropharmacology, 2016, 106: 20-34. doi:  10.1016/j.neuropharm.2015.12.014
[9] 赵妍, 林建生. 中枢组织胺H3受体在睡眠-觉醒调节中的功用及作为治疗睡眠障碍药物干预靶点的依据[J]. 生理科学进展, 2014, 45(1): 7-15.
[10]

GONDARD E, ANACLET C, AKAOKA H, et al. Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice[J]. Neuropsychopharmacology, 2013, 38(6): 1015-1031. doi:  10.1038/npp.2012.266
[11]

LIN J S, DAUVILLIERS Y, ARNULF I, et al. An inverse agonist of the histamine H(3)receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients[J]. Neurobiol Dis, 2008, 30(1): 74-83. doi:  10.1016/j.nbd.2007.12.003
[12]

LAMB Y N. Pitolisant: a review in narcolepsy with or without cataplexy[J]. CNS Drugs, 2020, 34(2): 207-218. doi:  10.1007/s40263-020-00703-x
[13]

SADEK B, SAAD A, SADEQ A, et al. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases[J]. Behav Brain Res, 2016, 312: 415-430. doi:  10.1016/j.bbr.2016.06.051
[14] 赵妍, 王治, 林建生, 等. 脑内组胺H3受体反向激动剂必妥利生(即替洛利生): 促醒及治疗睡眠和认知障碍新疗法[J]. 中国药理学通报, 2022, 38(11): 1622-1626.
[15]

LINDBERG F A, NORDENANKAR K, FREDRIKSSON R. SLC38A10 knockout mice display a decreased body weight and an increased risk-taking behavior in the open field test[J]. Front Behav Neurosci, 2022, 16: 840987. doi:  10.3389/fnbeh.2022.840987
[16]

WEITZNER D S, ENGLER-CHIURAZZI E B, KOTILINEK L A, et al. Morris water maze test: optimization for mouse strain and testing environment[J]. J Vis Exp, 2015(100): e52706.
[17]

BRABANT C, CHARLIER Y, TIRELLI E. The histamine H3-receptor inverse agonist pitolisant improves fear memory in mice[J]. Behav Brain Res, 2013, 243: 199-204. doi:  10.1016/j.bbr.2012.12.063
[18]

PARMENTIER R, ANACLET C, GUHENNEC C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders[J]. Biochem Pharmacol, 2007, 73(8): 1157-1171. doi:  10.1016/j.bcp.2007.01.002
[19]

KRIEF S, BERREBI-BERTRAND I, NAGMAR I, et al. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol[J]. Pharmacol Res Perspect, 2021, 9(5): e00855. doi:  10.1002/prp2.855